| Variable |
Group |
Dose |
|
|
|
|
| |
|
placebo |
caffeine 150 |
caffeine 300 |
d-amph 20 |
effect size, η2ρ |
| systolic BP |
control |
115.64 |
115.90 |
117.36 |
119.27 |
|
| |
|
(3.41) |
(4.07) |
(4.20) |
(2.13) |
|
| |
cocaine |
120.18 |
122.10 |
123.84 |
120.30 |
|
| |
|
(1.40) |
(1.81) |
(2.18) |
(1.58) |
|
| diastolic BP * |
control |
74.82 |
75.33 |
77.94 |
77.83 |
0.49 |
| |
|
(2.78) |
(2.72) |
(1.42) |
(1.45) |
|
| |
cocaine |
79.66 |
79.98 |
82.81 |
78.16 |
|
| |
|
(3.01) |
(1.79) |
(1.74) |
(1.56) |
|
| heart rate ** |
control |
66.10 |
62.47 |
61.33 |
65.55 |
0.53 |
| |
|
(1.88) |
(2.09) |
(1.67) |
(1.23) |
|
| |
cocaine |
63.08 |
62.60 |
61.57 |
63.51 |
|
| |
|
(2.11) |
(3.00) |
(1.40) |
(2.99) |
|
Means (delta-method robust standard errors) for cardiovascular measures across
placebo, 150 mg caffeine, 300 mg caffeine, and 20 mg d-amphetamine doses.
Data are averaged across the seven time points on each dose day, and shown
separately for control and cocaine-dependent groups
*= p < .05, main effect of dose, see text for details
**= p < .001, main effect of dose, see text for details |
